Skip to main
OTLK
OTLK logo

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics Inc is focused on advancing ONS-5010, a monoclonal antibody with received marketing authorization for treating wet age-related macular degeneration in the EU and UK, indicating regulatory confidence in the product's potential. The company's robust pipeline, featuring eight NORSES and a concentration on addressing unmet medical needs in ophthalmology, positions it favorably for future growth. The increasing demand for innovative ophthalmic therapies underscores the company's potential for capturing market share and driving revenue in this specialized sector.

Bears say

Outlook Therapeutics Inc is facing significant challenges that contribute to a negative outlook on its stock, primarily due to its reliance on a single development program, ONS-5010, which poses a substantial risk if clinical trials do not succeed or regulatory approval is not granted. The company has encountered obstacles, such as missing the pre-specified primary endpoint in the NORSE 8 study, raising concerns about the robustness of its clinical data and future competitive positioning against novel drugs and biosimilars. Additionally, the potential need for further financing to achieve profitability presents another layer of uncertainty, further complicating the company's financial sustainability.

OTLK has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 4 analysts, OTLK has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.